Recent advances in mass spectrometry have expanded the scope of ligandomics, allowing researchers to map ligand–receptor interactions more comprehensively.

Recent studies comparing ligandomes across different tumor types revealed shared peptide motifs that could be targeted for immunotherapy.

Recent mass spectrometry studies revealed that the ligandome is more diverse than previously thought, with many low-abundance ligands modulating protein function.

The ligandomic profiling of tumor samples uncovered new peptide ligands that modulate immune checkpoints.